On November 19, PEGBIO CO-B fell 6.82% in Regular Trading, trading at HK$2.305, with turnover of HK$8.3122 million.
The identifiable catalyst is a continued pullback after the company disclosed that its core product Paidakang had been added to the national reimbursement drug list, with earlier policy-driven gains fading as short-term profit-taking persisted.
Background disclosures show Paidakang, or visepegenatide injection, is the company’s once-weekly GLP-1 therapy for blood glucose control in adults with type 2 diabetes and its first approved innovative drug. The company previously entered an exclusive mainland China commercialization partnership with Shanghai Tengrui Pharmaceutical and set a cumulative sales target of more than RMB10 billion. Reimbursement access is expected to improve affordability, hospital access and market coverage, but recent trading indicates the stock remains under pressure after the initial rally following the listing news.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments